|
|
|
13.10.25 - 04:54
|
Hong Kong stocks post longest decline in 9 months on renewed US-China tensions (SCMP)
|
|
|
Hong Kong stocks fell for a sixth day on Monday, the longest losing streak in nine months, as a flare-up in US-China trade tensions kept investors on edge.
The Hang Seng Index fell 2.2 per cent to 25,705.68 as of 10.05am local time, matching a six-day run in early January. The Hang Seng Tech Index dropped 2.5 per cent.
On the mainland, the CSI 300 Index slid 1.7 per cent and the Shanghai Composite Index retreated 1.4 per cent.
Biotech major WuXi AppTec, which has a huge exposure to the US,......
|
|
|
|
|
|
|
09.10.25 - 06:15
|
Midday Takeaway: HSI Closes Midday at 26,840, Up 11 pts; HSTI Closes Midday at 6,555, Up 41 pts; HANG SENG BANK Up over 26%; HANG SENG BANK, ZIJIN MINING, WUXI APPTEC, CHINAHONGQIAO, SH ELECTRIC Hit New Highs (AAStocks)
|
|
|
At midday close, HSI rose 11 pts or 0.0% to 26,840. HSTI rose 41 pts or 0.6% to 6,555. HSCEI gained 49 pts or 0.5% to 9,573.Active Heavyweights:MEITUAN (03690.HK) closed at $104.5, up 0.8%BABA (09988.HK) closed at $176.4, down 0.7%XIAOMI (01810.HK) closed at $53.75, down 0.2%TENCENT (00700.HK) closed at $674.5, down 0.1%HSI & HS......
|
|
|
|
|
06.10.25 - 06:06
|
Australian AI healthcare start-up eyes Hong Kong, Singapore markets (SCMP)
|
|
|
Australian healthcare technology start-up Heidi has secured US$65 million in a new funding round, as it aims to expand its workforce and establish offices in Hong Kong and Singapore to capitalise on the growing demand for medical artificial intelligence technology in the region.
The company is valued at US$465 million following its series B round announced on Monday, led by Point72 Private Investments, a global alternative asset manager.
The six-year-old start-up planned to build a team of about......
|
|
|
|
|
|
|
02.10.25 - 10:36
|
Chinese healthcare, biotech firms flock to Hong Kong for IPOs (SCMP)
|
|
|
Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in the sector.
The best-known names among them are online healthcare services firm We Doctor Holdings, Sichuan Biokin Pharmaceutical – known for a US$8.4 billion licensing deal with US-based Bristol Myers Squibb (BMS) – and profitable cancer-drug developer Betta Pharmaceuticals.
Other initial public......
|
|
|
30.09.25 - 14:33
|
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia (GlobeNewswire EN)
|
|
|
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it has been invited to attend the J.P. Morgan Asset Management, Life Science Innovation Forum (LSIF) 2025 in Collaboration with KAIMRC, taking place October 1–2, 2025, at the King Saud bin Abdulaziz University for Health Sciences Conference Center in Riyadh, Saudi Arabia....
|
|
|
30.09.25 - 06:15
|
Midday Takeaway: HSI Closes Midday at 26,596, Down 25 pts; HSTI Closes Midday at 6,358, Up 34 pts; WUXI APPTEC Up over 5%; SMIC, HUA HONG SEMI, GANFENGLITHIUM, JIANGXI COPPER, UBTECH ROBOTICS Hit New Highs (AAStocks)
|
|
|
At midday close, HSI dropped 25 pts or 0.1% to 26,596. HSTI rose 34 pts or 0.5% to 6,358. HSCEI fell 11 pts or 0.1% to 9,442.Active Heavyweights:BABA (09988.HK) closed at $175.1, up 1%HKEX (00388.HK) closed at $439.2, down 0.7%MEITUAN (03690.HK) closed at $102.2, down 0.6%XIAOMI (01810.HK) closed at $53.35, down 0.4%TENCENT (007......
|
|
|
|
|
30.09.25 - 05:30
|
Research: UBS Ratings/ TPs on CN Pharmas (Table) (AAStocks)
|
|
|
Stock | Rating | TP (HKD)HENGRUI PHARMA (01276.HK) | Buy | 97.8 HANSOH PHARMA (03692.HK) | Buy | 48.2 SINO BIOPHARM (01177.HK) | Buy | 12.23SBIO (01530.HK) | Buy | 41 CSPC PHARMA (01093.HK) | Buy -> Neutral | 10 SIMCERE PHARMA (02096.HK) | Buy | 16.3HENGRUI PHARMA (600276.SH) | Buy | RMB78.6 HUADONG MEDICINE (000963.SZ) | Buy......
|
|
|
|
|
|
|
|
|
|
|
25.09.25 - 14:33
|
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody (GlobeNewswire EN)
|
|
|
BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis' recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program....
|
|
|
24.09.25 - 14:45
|
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress (GlobeNewswire EN)
|
|
|
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), being held September 24-26, 2025, in Barcelona, Spain. The ECTRIMS Congress is the world's largest annual international conference dedicated to basic and clinical research in multiple sclerosis. It brings together leading scientists, clinicians, and industry partners to share the latest advances in MS research and treatment....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
